Bayer Group Key Data

 

 

Q3 2017

 

Q3 2018

 

Change

 

9M 2017

 

9M 2018

 

Change

 

Full Year 2017

 

 

€ million

 

€ million

 

%

 

€ million

 

€ million

 

%

 

€ million

2017 figures restated

1

For definition see Annual Report 2017, Chapter “Alternative Performance Measures Used by the Bayer Group.”

2

Employees calculated as full-time equivalents (FTEs)

Sales

 

8,025

 

9,905

 

+23.4

 

26,419

 

28,524

 

+8.0

 

35,015

Change (adjusted for currency and portfolio effects)1

 

 

 

 

 

+1.9

 

 

 

 

 

+4.1

 

+1.5%

Change in sales1

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Volume

 

+2.2%

 

+2.8%

 

 

 

+1.3%

 

+5.3%

 

 

 

+2.3%

Price

 

−1.0%

 

−0.9%

 

 

 

−0.2%

 

−1.2%

 

 

 

−0.8%

Currency

 

−4.1%

 

−2.6%

 

 

 

−0.1%

 

−5.4%

 

 

 

−1.4%

Portfolio

 

+0.1%

 

+24.1%

 

 

 

+0.1%

 

+9.3%

 

 

 

+0.1%

EBITDA1

 

1,969

 

5,333

 

+170.8

 

7,103

 

10,168

 

+43.2

 

8,563

Special items1

 

(235)

 

3,131

 

 

 

(402)

 

2,735

 

 

 

(725)

EBITDA before special items1

 

2,204

 

2,202

 

−0.1

 

7,505

 

7,433

 

−1.0

 

9,288

EBITDA margin before special items1

 

27.5%

 

22.2%

 

 

 

28.4%

 

26.1%

 

 

 

26.5%

EBIT1

 

1,388

 

4,423

 

+218.7

 

5,278

 

8,084

 

+53.2

 

5,903

Special items1

 

(249)

 

3,123

 

 

 

(595)

 

2,682

 

 

 

(1,227)

EBIT before special items1

 

1,637

 

1,300

 

−20.6

 

5,873

 

5,402

 

−8.0

 

7,130

Financial result

 

(403)

 

(678)

 

−68.2

 

(1,068)

 

(870)

 

+18.5

 

(1,326)

Net income (from continuing and discontinued operations)

 

3,881

 

2,886

 

−25.6

 

7,188

 

5,639

 

−21.5

 

7,336

Earnings per share1 from continuing and discontinued operations (€)

 

4.38

 

2.94

 

−32.9

 

8.12

 

6.08

 

−25.1

 

8.29

Core earnings per share1 from continuing operations (€)

 

1.45

 

1.19

 

−17.9

 

5.25

 

4.92

 

−6.3

 

6.64

Net cash provided by operating activities (from continuing and discontinued operations)

 

2,711

 

2,051

 

−24.3

 

5,865

 

4,949

 

−15.6

 

8,134

Cash outflows for capital expenditures

 

557

 

659

 

+18.3

 

1,448

 

1,467

 

+1.3

 

2,418

Research and development expenses

 

1,079

 

1,180

 

+9.4

 

3,270

 

3,481

 

+6.5

 

4,504

Depreciation, amortization and impairments

 

581

 

910

 

+56.6

 

1,825

 

2,084

 

+14.2

 

2,660

Number of employees at end of period2

 

99,845

 

118,196

 

+18.4

 

99,845

 

118,196

 

+18.4

 

99,820

Personnel expenses (including pension expenses)

 

2,300

 

2,783

 

+21.0

 

7,281

 

7,787

 

+6.9

 

9,528

Compare to Last Year